COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,758 Articles (22,943 medRxiv, 8,815 bioRxiv)

Most recent first Previous |  Page 1081: Articles 10801-10810  | Next

Divergent SARS CoV-2 Omicron-specific T- and B-cell responses in COVID-19 vaccine recipients
GeurtsvanKessel, C. H., Geers, D., Schmitz, K. S., Mykytyn, A. Z., Lamers, M. M., Bogers, S., Gommers, L., Sablerolles, R. S. G., Nieuwkoop, N. N., Rijsbergen, L. C., van Dijk, L. L. A., de Wilde, J., Alblas, K., Breugem, T. I., Rijnders, B. J. A., de Jager, H., Weiskopf, D., van der Kuy, P. H. M., Sette, A., Koopmans, M. P. G., Grifoni, A., Haagmans, B. L., de Vries, R. D.
10.1101/2021.12.27.21268416 — Posted: 2021-12-29
Immunogenicity of heterologous BNT162b2 booster in fully vaccinated individuals with CoronaVac against SARS-CoV-2 variants Delta and Omicron: the Dominican Republic Experience
Perez-Then, E., Lucas, C., Monteiro, V. S., Miric, M., Brache, V., Cochon, L., Vogels, C. B. F., De la Cruz, E., Jorge, A., De los Santos, M., Leon, P., Breban, M. I., Billig, K., Yildirim, I., Pearson, C., Downing, R., Gagnon, E., Muyombwe, A., Razeq, J., Campbell, M., Ko, A., Omer, S. B., Grubaugh, N. D., Vermund, S. H., Iwasaki, A.
10.1101/2021.12.27.21268459 — Posted: 2021-12-29
Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in Japanese patients after allogeneic stem cell transplantation.
Watanabe, M., Yakushijin, K., Funakoshi, Y., Ohji, G., Sakai, H., Hojo, W., Saeki, M., Hirakawa, Y., Matsumoto, S., Sakai, R., Nagao, S., Kitao, A., Miyata, Y., Koyama, T., Saito, Y., Kawamoto, S., Ito, M., Murayama, T., Matsuoka, H., Minami, H.
10.1101/2021.12.28.21268477 — Posted: 2021-12-29
Capturing a crucial 'disorder-to-order transition' at the heart of the coronavirus molecular pathology - triggered by highly persistent, interchangeable salt-bridges
Roy, S., Ghosh, P., Bandyapadhyay, A., Basu, S.
10.1101/2021.12.29.474439 — Posted: 2021-12-29 Discussion: Onsite
Topological data analysis identifies distinct biomarker phenotypes during the inflammatory phase of COVID-19
Blair, P. W., Brandsma, J., Chenoweth, J. G., Richard, S. A., Epsi, N. J., Mehta, R., Striegel, D. A., Clemens, E. G., Lindholm, D. A., Maves, R. C., Larson, D. T., Mende, K., Colombo, R. E., Ganesan, A., Lalani, T., Colombo, C. J., Malloy, A. A., Snow, A. L., Schully, K. L., Lanteri, C., Simons, M. P., Dumler, J. S., Tribble, D., Burgess, T., Pollett, S., Agan, B. K., Clark, D. V., EPICC COVID-19 Cohort Study Group
10.1101/2021.12.25.21268206 — Posted: 2021-12-29
Vaccine effectiveness against hospital admission in South African health care workers who received a homologous booster of Ad26.COV2 during an Omicron COVID19 wave: Preliminary Results of the Sisonke 2 Study.
Gray, G. E., COLLIE, S., Garrett, N., Goga, A., Champion, J., Zylstra, M., Reddy, T., Yende, N., Seocharan, I., Takalani, A., Sanne, I., Mayat, F., Odhiambo, J., Bamford, L., Moultrie, H., Fairall, L., Bekker, L.-G.
10.1101/2021.12.28.21268436 — Posted: 2021-12-29 Discussion: Onsite
Dynamic Expedition of Leading Mutations in SARS-CoV-2 Spike Glycoproteins
He, Z., Hasan, M., Jia, M., Natarajan, K., Yap, S. Q., Zhou, F., Su, H., Zhu, K., Su, H.
10.1101/2021.12.29.474427 — Posted: 2021-12-29
Functional properties of the spike glycoprotein of the emerging SARS-CoV-2 variant B.1.1.529
Wang, Q., Anang, S., Iketani, S., Guo, Y., Liu, L., Ho, D. D., Sodroski, J. G.
10.1101/2021.12.27.474288 — Posted: 2021-12-29
mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2
Darling, T. L., Ying, B., Whitener, B., VanBlargan, L., Bricker, T. L., Liang, C.-Y., Joshi, A., Bamunuarachchi, G., Seehra, K., Schmitz, A., Halfmann, P., Kawaoka, Y., Elbashir, S., Edwards, D. K., Thackray, L., Diamond, M., Boon, A.
10.1101/2021.12.29.474432 — Posted: 2021-12-29
A Novel CRISPR-Engineered, Stem Cell-Derived Cellular Vaccine
Chakraborty, K., Chandrashekar, A., Sidaway, A., Latta, E., Yu, J., McMahan, K., Manickam, C., Kroll, K., Mosher, M., Reeves, R. K., Gam, R., Arthofer, E., Choudhry, M., Barouch, D. H., Henley, T.
10.1101/2021.12.28.474336 — Posted: 2021-12-29

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).